Brain metastasis occurs when cancer in one part of the body spreads to the brain. The lifetime incidence of such metastatic brain tumors in cancer patients is between 20%-45%, research shows.
A multifaceted microfluidic in vitro assay is helping to identify the role of hypoxia on red blood cell aging via the biomechanical pathways. It holds promise for investigating hypoxic effects on the metastatic potential and relevant drug resistance of cancer cells.
In human cancer cell and mouse studies, researchers from Johns Hopkins Medicine have found that a set of proteins work in tandem to build supply lines that deliver oxygen and nutrients to tumors, enabling them to survive and grow. The protein twosome, PADI4 and HIF-1, ramp up their activity under low-oxygen conditions that are typically found in a fast-growing tumor, allowing it to build new blood vessels that feed the cancer’s growth.
MIT engineers, in collaboration with scientists at Cancer Research UK Manchester Institute, have developed a new way to grow tiny replicas of the pancreas, using either healthy or cancerous pancreatic cells.
Article title: Ethyl isopropyl amiloride decreases oxidative phosphorylation and increases mitochondrial fusion in clonal untransformed and cancer cells Authors: Sagar S. Manoli, Kyle Kisor, Bradley A. Webb, Diane L. Barber From the authors: “Our findings that a lower [intracellular pH (pHi)]…
In a bid to find or refine laboratory research models for cancer that better compare with what happens in living people, Johns Hopkins Medicine scientists report they have developed a new computer-based technique showing that human cancer cells grown in culture dishes are the least genetically similar to their human sources.
Ruomei Gao—an associate professor at SUNY College at Old Westbury—has been using facilities at the Center for Functional Nanomaterials at Brookhaven Lab to investigate two primary processes of photosensitization for cancer therapy and prevention.
A dysfunctional immune system significantly contributes to the development of cancer. Several therapeutic strategies to activate the immune system to target cancer cells have been approved to treat different types of cancer, including melanoma.
One specific protein may be a master regulator for changing how cancer cells consume nutrients from their environments, preventing cell death and increasing the likelihood the cancer could spread, a study from the University of Notre Dame has shown.
A Mayo Clinic team, led by Rahmi Oklu, M.D., Ph.D., a vascular and interventional radiologist at Mayo Clinic, in collaboration with Samir Mitragotri, Ph.D., of Harvard University, report the development of a new ionic liquid formulation that killed cancer cells and allowed uniform distribution of a chemotherapy drug into liver tumors and other solid tumors in the lab.
Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that blocking the construction of nuclear pores complexes—large channels that control the flow of materials in and out of the cell nucleus—shrank aggressive tumors in mice while leaving healthy cells unharmed. The study, published in Cancer Discovery, a journal of the American Association for Cancer Research, reveals a new Achilles heel for cancer that may lead to better treatments for deadly tumors such as melanoma, leukemia and colorectal cancer.